Pre-earnings options volume in Crispr Therapeutics is normal with puts leading calls 9:8. Implied volatility suggests the market is anticipating a move near 7.2%, or $5.65, after results are released. Median move over the past eight quarters is 7.6%.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
- Crispr Therapeutics initiated with a Peer Perform at Wolfe Research
- Cathie Wood’s ARK Investment bought 280K shares of Crispr Therapeutics today
- Crispr Therapeutics Secures Funding Through Share Issuance
- Crispr Therapeutics announces $280M registered diect offering